U.S. Markets open in 5 hrs 45 mins

Jazz Pharmaceuticals Public Limited Company (JAZZ)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
146.01-1.39 (-0.94%)
At close: 4:00PM EDT
People also watch
ALXNBMRNREGNICPTMDVN
  • A
    Abraham
    Abraham

    SNOA (MC $23 M) (Cash $13 M) Shares Out: 4.3 M / 17 FDA approved products some of them are in early launch phase plus additional Product launches expected within 6 months / Profitable in 2018 = 1000%+ UPSIDE POTENTIAL..GLTA

    Sonoma Pharma (Nasdaq: SNOA)

    Market Cap: 22.1 Million
    Cash: $12.6 Million
    Price: $5.15

    Shares Out : 4.3 Million

    Presentation
    http://ir.sonomapharma.com/common/download/download.cfm?companyid=ocls&fileid=945547&filekey=F57B6874-6CD1-4205-A160-8E08BBB7A928&filename=SonomaPharma_Investor_presentation_13June2017.pdf

    Fact Sheet
    http://files.shareholder.com/downloads/OCLS/4977255852x0x231236/39d834a3-8462-40ee-8650-e0945b6facd5/Sonoma_Fact_Sheet.pdf

    Driving to commercial EBITDAS breakeven, without dilution

    Grow current product portfolio with all sales people

    •Alevicyn HydroGel, Dermal Spray & Spray Gel for atopic dermatitis & dermal procedures •Celacyn for scar treatment
    •Mondoxyne for severe acne –launched late 2015
    •Ceramax for skin repair in atopic dermatitis–launched in April 2016
    •SebuDerm for seborrhea dermatitis –launched in November 2016

    Launch 3 New Products –our product pipeline –one every other quarter

    •Launching Loyon–Fall 2017
    •Ceramax in foam and gel forms –Q4 2017 & Q1 2018

    Launch and Grow New and Current Products: During fiscal year 2017, we launched four new dermatology products, including SebuDerm™, Ceramax™, Lasercyn™ Gel and Lasercyn™ Dermal Spray, bringing us to a total of eight dermatology products for the treatment of atopic and seborrheic dermatitis, scar management, surgical procedures, severe acne and “state of the art” skin repair technology. We also obtained three new FDA clearances, now totaling 16 overall. Our strong intellectual property portfolio consists of 63 issued patents and 33 patent applications pending.

    We plan to launch our new FDA approved product Loyon® (a skin descaler currently marketed in Europe) in the upcoming months and have a strong product pipeline of several product line improvements, including a line extension of Ceramax™. All in all, we believe this could possibly be our best product line of new FDA approved dermatology and skincare products yet, and we believe our innovation plan will help lead us to profitability.

  • A
    Anna
    Anna
    Is JAZZ undervalued? This sort of setup suggests potential upside... Do you guys find it difficult to know when to buy or sell something? I prefer to get my stocks from awe*some*sto-ck*s.
  • C
    Chloe
    Chloe
    If we are to go off the RSI then you could argue that a pull back next day or so could occur on JAZZ before rallying up. have you guys heard of Awe-Som.e.Sto-cks.. i started receiving their allerts and so far i am happy.
  • S
    Steve
    Steve
    why is the beta so high with Jazz. any thoughts?
  • N
    Nick
    Nick
    9 billion plus 2 billion in debt. There has to be someone holding this stock up fraudulently. Companies with deep pipelines and blockbuster products have gotten decimated and this stock is worth 11 billion? how can this be?
  • N
    Nick
    Nick
    look how manipulated this stock is. the company is absolute toast horrible earnings with a 1 product company basically which is a few years away from a generic and less than a year away from a brand of sodium oxybate being approved from avadel. There are other 2 products were aquired for 1.75 billion and in my opinion are dead in the water. How these crooks are holding this stock up has been an absolute fraud
  • N
    Nick
    Nick
    are these crooks just trading the stock so they can burn who ever iks short the stock. merely because we see that this is a fraud?
  • B
    Benedetto
    Benedetto

    This is where I find the top NASDAQ & NYSE Trade Ideas ---> www.T0pm@rketgainers.c0m

  • T
    Temple
    Temple

    This is where I find the top NASDAQ & NYSE Trade Ideas ---> www.T0pm@rketgainers.c0m

  • C
    Crecy
    Crecy
    JAZZ owns EUSA Pharma. EUSA is in partnership with AVEO....AVEO has Tivozanib, a treatment for Advanced Renal Cell Carcinoma. Tivozanib was recently Recommended for Approval in the EU. The Approval date is end of Aug. August starts tomorrow. Would JAZZ be interested in getting their hands on Tivozanib?
  • H
    Hercule
    Hercule
    T0pMarketGaIners.c0m is one of the best “alerts” services I have found. Just sign up and watch from the sidelines, you will see!
  • M
    Mackenzie
    Mackenzie
    The upside potential for JAZZ just got a whole lot more interesting. Ive been struggling with this stock lately. Some of my other trades have been from awesome_stocks which are working out pretty well.
  • J
    Jasmine
    Jasmine
    I have a feeling JAZZ will see a pullback now. What yall think? This is so frustrating trying to find trade ideas. I've subscribed to some email newsletters which helps me with new stock ideas. awesome*stocks is the one i like best.
  • A
    Anonymous
    Anonymous

    [!] Option spread traders check out CreditSpreads.io, zero cost live feed of mathematically gainful option credit spreads for the coming month, sometimes including spreads for JAZZ! High-probability option credit spreads offer you an approach to trade with defined risk and the max profit received right away. CreditSpreads.io lazer-targets solely the option spreads which meet its strict requirements for risk and profit, and ensures continued profitability by warning you of any impending catalysts that may affect the trade. www.creditspreads.io

    CreditSpreads.io
    Sustainable, high probability, defined risk stock option trading opportunities.
    www.creditspreads.io
  • J
    Jeffrey
    Jeffrey
    check their website for pipeline. Like it or not if they get FDA approval for an oral agent for OSA this stock could double
  • M
    Maccius
    Maccius

    Decem unius majus est sol decem lineis per gradus.http://dataunion.tistory.com/9528

    [2016-SEP] Jazz Pharmaceuticals plc - Ordinary Shares NASDAQ : JAZZ Correlation Histogram
    X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks Sep-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is 0.8 In other words, the correlation coefficient of the other stock
    dataunion.tistory.com
  • Y
    Yahoo Finance Insights
    Yahoo Finance Insights
    JAZZ is up 5.16% to 152.68
  • H
    HotPicks
    HotPicks
    Its like buying JAZZ at $1 a few years ago now trading at $151
    (AXSM) Market Cap $90 M/Cash $55 M / 5x BIG Phase 3 programs in various indications targeting large Markets with first results in Q3 2017 =20 BAGGER ..FANTASTIC OPPORTUNITY !

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $90 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $90 Million
    Cash: $55 Million(cash runway into the first quarter of 2019.)
    Price:$3.90

    Shares Out: 23.5 Million

    Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.
  • N
    Nick
    Nick
    Comapnies like jazz who are charging billions of dollars for drugs whose patents should have expired a long time ago and let generics hit the market have destroyed American families. We pay 30 thousand a year for health care so that these pharma companies can make hedge funds and other wall st crooks rich and ofcourse jazz executives rich while we suffer. Less time with our families less vacation etc. Our quality of life has been destroyed so they can have their mansions and good life.
  • N
    Nick
    Nick
    I am very eager to see what jazz is up to in the near future to manipulate it's stock higher. They are always up to something some announcement that makes xyrem and themselves above the law. These market makers are a bunch of criminals and manipulate the stock on inside info